Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Interest Expense

Cost of servicing the company's debt during the period.

Nanobiotix S.A.NASDAQ: NBTX

Interest Expense · Q4 FY2025 · quarter ended Dec 2025

Interest expense remains negative

Q4 FY2025 interest expense was €6.75M, compared with €0 a year earlier. Over 3 fiscal years it compounded at +21.2% a year.

Context

  • Interest expense amounted to 35.1% of revenue in FY2025.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€6.75M— QoQ
Last fiscal yearDec 2025
€10.4M+28.6% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+28.6%——
3-year CAGR+21.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
10.4M EUR
Year-over-year change
+28.6%
4-year CAGR
+96.3%

Interest Expense vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.6% is the 3rd highest of 6, against a peer median of -8.5%.
  • Interest expense amounts to 35.1% of revenue for NBTX, versus a peer median of 19.7%.
NBTX Competitors
Interest Expense for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$87.69M USD-12.5%+33.6%48.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$80.69M USD+524.3%+120.8%37.2%
NBTXNanobiotix S.A.FY2025€10.4M EUR+28.6%+21.2%35.1%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$5.18M USD-54.1%-17.0%2.3%
CADLCandel Therapeutics, Inc.LTM Mar 2026$3.38M USD+93.0%+7.5%—
KURAKura Oncology, Inc.LTM Mar 2026$1.47M USD-8.5%+87.6%2.0%
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding NBTX) —-8.5%+33.6%19.7%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.